Get the Stockscreener App
548.05
1.44%
7.79
After Hours:
548.05
Vertex Pharmaceuticals Inc stock is traded at $548.05, with a volume of 1.07M.
It is up +1.44% in the last 24 hours and up +13.70% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$540.26
Open:
$545.1
24h Volume:
1.07M
Relative Volume:
0.70
Market Cap:
$138.91B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
32.49
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+8.36%
1M Performance:
+13.70%
6M Performance:
+14.92%
1Y Performance:
+37.89%
1-Day Range:
$540.70
$555.32
1-Week Range:
$502.53
$555.32
52-Week Range:
$374.17
$555.32
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? - The Globe and Mail
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? - The Motley Fool
Why Is Vertex Pharmaceuticals (NASDAQ:VRTX) Pipeline Value in Focus? - Kalkine Media
Vise Technologies Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Trillium Asset Management LLC Acquires New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
PCM Encore LLC Invests $1.06 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Metzler seel. Sohn & Co. AG Acquires Shares of 231,381 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of New York Mellon Corp Purchases Shares of 1,672,623 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Reinforces Dominance in Cystic Fibrosis Market as Competitor Falters - SSBCrack
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - AOL.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Enters New Healthcare Focus - Kalkine Media
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Madison Asset Management LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Somerville Kurt F Invests $8.17 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Westport Asset Management Inc. Purchases New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
8,423 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Notis McConarty Edward - MarketBeat
Puzo Michael J Purchases Shares of 15,907 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
11,305 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by NewEdge Wealth LLC - MarketBeat
Knuff & Co LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
DCF Advisers LLC Invests $5.71 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Are Wall Street Analysts Bullish on Vertex Stock? - Barchart.com
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Up by 4.48% on Aug 19: Drivers Behind the Movement - TradingKey
Crinetics (CRNX) projects $1B+ 2030 revenue for Vertex deal - Stock Titan
What Is Putting Vertex Pharmaceuticals (NASDAQ:VRTX) Under the Spotlight? - Kalkine Media
Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year HighHere's What Happened - MarketBeat
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD - Investing.com
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD By Investing.com - Investing.com South Africa
0000875320-22-000017 | 8-K - Vertex Pharmaceuticals Newsroom
Wealthfront Advisers LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Meeder Advisory Services Inc. Buys Shares of 6,415 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Pallas Capital Advisors LLC Takes $1.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Danske Bank A S Takes $78.52 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
27,829 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Danica Pension Livsforsikringsaktieselskab - MarketBeat
Vertex Pharma stock holds at record levels as analysts highlight competitive win - Ad-hoc-news.de
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600 - Moomoo
Bernstein Names Top Biotech Stock Pick: Vertex Leads After Rival Drug Fails - Investing.com Nigeria
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
UNIVEST FINANCIAL Corp Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Perigon Wealth Management LLC Takes $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Citizens Financial Group Inc. RI Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cornerstone Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
6,857 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Commerzbank Aktiengesellschaft FI - MarketBeat
Deutsche Bank AG Invests $784.39 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
BlackRock Inc. Invests $11.98 Billion in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):